Organization

António Horta-Osório graduated in Business Management and Administration from the Portuguese Catholic University (1987), having completed an MBA at INSEAD in 1991 and an Advanced Management Program at Harvard Business School in 2003.

He has had a long and successful career in banking, which began in 1987 at Citibank, followed by Goldman Sachs in New York and London. In 1993 he joined the Santander Group and created Banco Santander de Negócios Portugal (BSNP), becoming its CEO. He has held various management positions in Santander as CEO in Portugal, Brazil and the United Kingdom, where he transformed Abbey National, acquired Alliance & Leicester and Bradford & Bingley during the Great Financial Crisis and merged them into Santander UK in 2010. In 2000, he was appointed Executive Vice President of the Santander Group and a member of the Management Committee. In a personal capacity, he was Non-Executive Director of the Bank of England between 2009 and 2011.

In 2011 he was appointed Chief Executive Officer at Lloyds Banking Group, at the invitation of the UK Government, to lead the turnaround of the Bank, partially nationalised, following Lloyds' acquisition of HBOS, and succeeded in returning the bank to private ownership in 2017, with full repayment of taxpayers' money.

In May 2021 he took office as Chairman of the Board of Credit Suisse, a position he held until January 2022.

In June 2021 he was knighted by Queen Elizabeth II for his work in banking and voluntary services in the areas of mental health and culture. He has received several honorary doctorates from universities in the UK and the Portuguese Catholic University. Among other honours, he has been awarded the Grand Cross of the Order of Merit (Commercial Class), by the President of the Portuguese Republic; the Encomienda de Numero of the Order of Isabella the Catholic, by H.R.H. the King of Spain; and the title of Commander of the National Order of the Southern Cross, by the Brazilian Government.

Since April 2021, he has been Chairman of the Board of Directors of BIAL. He is Vice-Chairman of the Board of Directors and Chairman of the Strategy Committee of the Impresa media group (since September 2022). He has been a non-executive director of the Champalimaud Foundation since 2011; non-executive director of INPAR, holding of the Lemann family, since 2014; non-executive director of José de Mello (since September 2022) and a Senior Advisor at Mediobanca and Cerberus.

Married, he is the father of three children. His hobbies include tennis, diving, collecting Portuguese decorative arts and chess. He has Portuguese and British nationality.

António Portela holds a degree in Economics from the Faculty of Economics at the University of Porto and an Executive MBA from the Porto Business School. He began his professional activity at Roche pharmaceuticals in the United Kingdom, where he was a Medical Sales Representative and a Market Analyst for the oncology and haematology Business Units. He was also responsible for the Roche European Business Platform and, while still at Roche in the UK, was Product Manager for Hepatitis C.

He returned to Portugal in 2004 to join the BIAL team as Deputy Director of Marketing for Portugal. A member of the Board of Directors since 2007, he assumed the General Management of the International Department for three years, having been responsible for the expansion of the business, for the entry of the BIAL group into new countries, and for the coordination of new product launches internationally.

In January 2011 he became CEO of BIAL, marking the arrival of the fourth generation of the family at the head of the company founded in 1924 by his great-grandfather Álvaro Portela.

Among his other roles, he is Chairman of the General Board of COTEC Portugal (since May 2022), Member of the Board of Founders of Serralves (since May 2021), Trustee of the University of Porto Foundation (since December 2018), and a member of the General Board of EFPIA - European Federation of Pharmaceutical Industries and Association (since June 2017).

He is a member of the Board of Directors of MAPFRE Seguros Gerais, SA (since July 2015), a member of the General Council of AEP – Associação Empresarial de Portugal (since May 2014), and a member of the Committee for Trade and Foreign Investment of AICEP - Agência para o Investimento e Comércio Externo de Portugal (since April 2013).

Joerg has a degree in Chemistry and acquired his Ph.D. in Germany on the synthesis of alkaloids as antimalarial agents. His professional career started in 1998 at Grünenthal Pharmaceuticals in Germany, where he led preclinical and clinical activities of the marketed analgesic Tapentadol (Nucynta/Palexia). From 2003 to 2006, he served as Head of Medicinal Chemistry at Barcelona-based Laboratórios Esteve. In 2006, Joerg joined AstraZeneca’s CNS/Pain Research Unit in Södertälje, Sweden, as Neuroscience Project Leader and Head of Lead Generation.

In 2012, Joerg moved to the US as Director for Research and Preclinical Sciences within AstraZeneca’s virtual Neuroscience Unit in Boston, and in this role was responsible for pioneering a novel concept of driving Research and Development via increased use of academic and industry collaborative networks. In 2016, Joerg build up the Neuroscience Proof-of-Concept unit for GlaxoSmithKline in Upper Providence, PA, and within three years created an innovative portfolio of clinical assets within Neuroimmunology. In 2018, Joerg joined Grünenthal as SVP of Neuroscience, based in Cambridge, US, and worked on designing and executing on the company’s new R&D organisation, its portfolio, as well as delivering a company-wide Pain disease area strategy. Joerg then built the Grünenthal Pain Innovation Hub in Cambridge, MA from 2019 to 2021.

In November 2021, BIAL appointed Joerg Holenz as General Manager of R&D, and, from March 2023, as Executive Vice-President and as BIAL's Chief Scientific Officer.

Throughout his career, Joerg worked predominantly with peripheral and central targets in the Pain and Neuroscience disease areas, where he delivered several SME and New Modality clinical candidates, as well as one marketed analgesic. He has edited, authored or contributed to more than 45 publications, 50 patent applications and several books and book chapters. In his free time, Joerg enjoys his family and two children, outdoor activities and traveling.

Max Bricchi has over twenty-five years of experience and leadership across Regional and Global Strategy, Marketing, Commercial, and end-to-end Portfolio Management. Max brings broad experience in the pharmaceutical industry from several roles, having a strong track record in pre-launch and launch of products across several therapeutical areas, including neurology, rheumatology, gastroenterology, dermatology and rare diseases.

Max Bricchi joined BIAL on 1 March 2023 as Chief Commercial Officer (CCO) and Executive Board Member, coming from Novartis (HQ, Basel, Switzerland) where, since 2020, he served as the Global Head Neuroscience Franchise. For 15 years, from 2005 to 2020, Max Bricchi served at UCB Pharma, where he undertook different positions in various locations of the company: Global Head Epilepsy Franchise, Japan, China and International Markets Head Neurology - both positions in Belgium -, Latin America Region Managing Director in Mexico, US Group Director Immunology and Global and US Brand Director Biologics in the United States.

Max Bricchi’s professional career in the pharmaceutical industry started in 2002 at Schering-Plough Corporation as Global Product Manager of Immunology, in the US, and then in Germany as Immunology Division Manager.

Max Bricchi holds an MBA from IMD Lausanne, a Master’s in Quality Management from Buenos Aires Technologic Institute and a degree as an Industrial Engineer from the University of Buenos Aires, Argentina.

José Redondo completed a degree in Economics from the Faculty of Economics of the University of Porto (1983) and holds a Master's in Economics with a specialisation in Industrial and Business Economics (1993) from the same University.

He joined BIAL in 1986 and has been a Member of the Board of Directors of BIAL Holding, S.A. and of several BIAL Group companies since 1993.

José is currently Executive Vice-President of Finance and Operations, responsible for Finance, Management Control, Industrial, Quality and Supply Chain, and is CFO of the BIAL Group, having previously held, among other positions, that of General Director of Finance and Operations (2021-2023), General Director of the Financial and Industrial Area (2019-2021), General Director of the BIAL Portugal Area (2007-2019), General Director of the BIAL International Area (2001-2007), Executive Vice President of BIAL Spain (1998-2007), and Chief Financial and Administrative Officer (1991-1998). Early in his career at BIAL he was also responsible for the Planning Office (1990) and was a Specialist in the Economic Advisory Office (1985-1989).

He taught at the Faculty of Economics at the University of Porto from 1983 to 1997, having taught several subjects in the course of Economics (Macroeconomics, Public Economics, Currency and Financing, International Monetary Economics) and Management (Organisational Structures).

In 1983-1984 he was a Technician at ICEP (now AICEP) with roles in the department of export incentives and in sectoral support to companies (paper and pulp).

He is currently also Chairman of the Supervisory Board of IBMC (Institute of Molecular and Cellular Biology) and of i3S (an association that brings together three institutes: IBMC, INEB - Biomedical Engineering Institute, and IPATIMUP - Molecular Pathology Institute). Representing the BIAL Group, he participates in the management of various entities as a member of the Board of Trustees, including of the CIP (the Business Confederation of Portugal), of the National Health Council of Portugal, of APGEI (Portuguese Association of Industrial Management and Engineering), and of APIFARMA (Portuguese Association of the Pharmaceutical Industry), and, as Vice-Chairman, of AEBA (Baixo Ave Business Association).

Born in 1978 in Porto, Miguel Portela has a degree in Economics from the Faculty of Economics at the University of Porto. He has taken several courses at the most prestigious management schools in Europe: Porto Business School, IESE Barcelona, London Business School, IMD Lausanne and IE Madrid. He began his professional activity at the BIAL Group as an intern in the Production, Warehouse, Marketing and Sales, Human Resources, Procurement, Finance and Economic Advisory Departments. In 2005, after having worked as a Technician in the New Projects Department, he was appointed General Management Technician, providing support to the General Manager of Bial Portugal. In 2007, he became the head of the company's Human Resources and Logistics departments, having been appointed Manager. From September 2010 to February 2023, Miguel accumulated the functions of Director and General Manager of the Corporate Area of the BIAL Group: Human Resources, Information Systems, Legal, Intellectual Property and Data Protection, Regulatory, and Audit & Compliance. Since March 2023, he is Executive Vice-President and Chief Corporate Officer, maintaining the same areas of responsibility.

He has been a Director of the Bial Foundation since February 2013 and, since April 2015, a Member of the Porto Business School Supervisory Board. In May 2021, he became a Member of the Founding Board of the Casa da Música Foundation and, since December of that same year, has been a Member of the Board of Trustees of the AEP Foundation (FAEP).

He was a top-level competitive swimmer in swimming, having been national champion for six consecutive years, breaking several national records – with emphasis on the 50, 100 and 200 freestyle – and having also represented his country’s national team.

With a career spanning over 35 years in the healthcare sector, Richard Pilnik joined the Board of Directors of BIAL as a non-executive member.

Richard Pilnik worked at US pharmaceutical company Eli Lilly for 25 years, where he held various positions. As CEO and President for Europe, the Middle East and Africa he has overseen over 50 countries with a turnover of over €4 billion, making Eli Lilly the fastest growing pharmaceutical company in the region.

In 2014, Richard Pilnik retired from Quintiles Transnational as Executive Vice President and President of Global Commercial Solutions, having joined the management team that launched the company's IPO on the New York Stock Exchange.

Richard Pilnik holds management positions at Diamedica and Duke University's Fuqua School of Business, and also works as a consultant for several companies.